LogicBio Therapeutics logo
LogicBio Therapeutics LOGC
report update icon

Quarterly report 2022-Q3
added 05-16-2026

LogicBio Therapeutics Book Value | LOGC

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value LogicBio Therapeutics

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
30.7 M 61.4 M 42.3 M 80.2 M 24.5 M -3.25 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
80.2 M -3.25 M 39.3 M

Quarterly Book Value LogicBio Therapeutics

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- 15.7 M 20.7 M 24.9 M 30.7 M 38.8 M 44.8 M 54.2 M 61.4 M 22.3 M 28.2 M 33.7 M 42.3 M 53.2 M 54.7 M 72.8 M 80.2 M 14.4 M 82.9 M 80.2 M 24.5 M 24.5 M - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
82.9 M 14.4 M 43.1 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
11.6 M - -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
57 M - - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
125 M - - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
86.2 M - - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
-38.9 M - - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
648 M - - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
190 M - - $ 2.36 B usaUSA
Annexon Annexon
ANNX
212 M $ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
63.9 M - 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
-27.2 M - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
3.24 B - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
7.16 M - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
1.83 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
18.6 M $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
21.5 M $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
154 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
27.3 M - - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
98.7 M - -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
4.16 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
80 M - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
928 M - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
-473 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
2.53 M - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
38.9 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
750 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
205 M - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
78.4 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
8.15 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
46.8 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
234 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
156 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
15.1 M - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
163 M - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
-4.08 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
-914 K - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-8.14 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-45.3 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
6.12 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
188 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
176 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
-31.5 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
31.8 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
66.9 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-11.9 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
39.1 M - - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
76.4 M - - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
149 M - - $ 127 M usaUSA
Aravive Aravive
ARAV
10.7 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
69.5 M - - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
992 M $ 84.95 0.13 % $ 7.99 B usaUSA